These 10 stocks could mint the next wave of millionaires › IDEAYA Biosciences (NASDAQ:IDYA), a precision oncology company focused on developing targeted therapies for cancer, reported its ...

Out-licensing drugs to multinational corporations is a natural step for Chinese biotechs, but the recent rise in deals is ...

Deal with DoveTree, established by Harvard professor Gregory Verdine, adds to growing list of licensing tie-ups with Chinese ...

The market for chronic obstructive pulmonary disease treatment devices is projected to witness substantial growth, fueled by ...

Amgen’s Bkemv is first FDA-approved biosimilar to AstraZeneca’s Soliris in the US, getting interchangeable status for rare diseases PNH and aHUS.